Previous research revealed a strong link between the concentration of Aβ/tau in cerebrospinal fluid (CSF) and cognitive impairment, suggesting that tau may serve as a viable biomarker for the diagnosis of AD (Jia et al., 2019; Wang et al., 2020). Here, MAPT is linked to Alzheimer disease.